Published in Pediatr Blood Cancer on January 01, 2008
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99
Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.66
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol (2011) 1.30
Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer (2012) 1.29
Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2010) 1.24
Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies. Am J Pathol (2010) 1.14
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer (2009) 1.08
Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2010) 1.05
Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 1.04
Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.03
Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2012) 1.03
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.03
Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2011) 0.98
Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer (2009) 0.95
Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer (2009) 0.95
A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol (2013) 0.95
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer (2012) 0.94
FOXM1 is an oncogenic mediator in Ewing Sarcoma. PLoS One (2013) 0.94
The application of radiation therapy to the Pediatric Preclinical Testing Program (PPTP): results of a pilot study in rhabdomyosarcoma. Pediatr Blood Cancer (2012) 0.90
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer (2014) 0.90
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica (2013) 0.89
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer (2014) 0.89
Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clin Cancer Res (2015) 0.88
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. J Neurosurg (2013) 0.88
Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials. Curr Oncol Rep (2008) 0.88
Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr Blood Cancer (2014) 0.87
Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.87
Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 0.87
Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol (2010) 0.86
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer (2012) 0.86
Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA Clin (2014) 0.86
Novel targeted drug therapies for the treatment of childhood acute leukemia. Expert Rev Hematol (2009) 0.85
Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 0.85
Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.83
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2013) 0.83
Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma. Oncotarget (2015) 0.83
From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. J Natl Cancer Inst (2013) 0.82
Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.82
Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 0.81
PAX3-FOXO1 induces up-regulation of Noxa sensitizing alveolar rhabdomyosarcoma cells to apoptosis. Neoplasia (2013) 0.81
Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro. BMC Cancer (2012) 0.81
Initial testing of aplidin by the pediatric pre-clinical testing program. Pediatr Blood Cancer (2009) 0.80
Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors. Cancer Res (2016) 0.79
Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.79
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2013) 0.78
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget (2016) 0.77
Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL. Bone Marrow Transplant (2016) 0.77
Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.77
A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program. Leukemia (2016) 0.76
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. J Hematol Oncol (2016) 0.75
Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future. Pharmaceuticals (Basel) (2016) 0.75
Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant. Cancer Res (2016) 0.75
Acute lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition. Oncotarget (2017) 0.75
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol (2002) 8.03
Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol (2009) 5.12
Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92
The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res (2009) 4.53
Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms. Nucleic Acids Res (2008) 4.22
Copy number variation at 1q21.1 associated with neuroblastoma. Nature (2009) 4.10
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol (2013) 3.70
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38
Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol (2005) 3.36
STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res (2006) 3.21
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99
Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 2.92
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res (2008) 2.77
The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol (2010) 2.59
Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA (2012) 2.49
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet (2009) 2.47
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res (2006) 2.42
A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther (2007) 2.35
Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol (2012) 2.32
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol (2013) 2.25
Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature (2010) 2.21
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition. Chem Biol (2003) 2.05
Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy. Genome Res (2009) 2.02
The role of chest computed tomography (CT) as a surveillance tool in children with high-risk neuroblastoma. Pediatr Blood Cancer (2015) 1.97
Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med (2011) 1.96
Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res (2004) 1.93
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev (2008) 1.93
Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer (2007) 1.93
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res (2006) 1.91
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A (2011) 1.90
Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene (2005) 1.86
Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res (2008) 1.84
Pediatric horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions. Am J Ophthalmol (2006) 1.81
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res (2009) 1.79
Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res (2009) 1.77
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog (2007) 1.74
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet (2012) 1.74
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol (2005) 1.74
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol (2007) 1.73
Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One (2007) 1.72
ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell (2012) 1.71
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.71
Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res (2007) 1.71
CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst (2008) 1.71
E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res (2007) 1.70
High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res (2006) 1.68
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther (2005) 1.66
Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.66
Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet (2004) 1.66
Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer (2006) 1.66
Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol (2007) 1.61
Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol (2005) 1.60